# All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi

Source: https://onco.cc/trials/nct06636981/  
OnCo record `nct06636981` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of toripalimab in triple-negative breast cancer, run by Fudan University, now recruiting.

## Summary

All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial is a phase 2, interventional study registered as NCT06636981 by Fudan University, with a registry enrolment figure of 129 participants, started 2024-11-04 and due to reach its primary completion in 2029-09. Interventions recorded: Cohort2: ATRA+Toripalimab+TPC; Cohort1: ATRA+Toripalimab+chemo. Conditions listed: Triple Negative Breast Cancer (TNBC). Triple-negative eligibility wording from the registry: "Cohort 1: For locally advanced non operable or metastatic TNBC that has not been previously treated, intravenous chemotherapy and anti-tumor therapy may be used during previous neoadjuvant and/or adjuvant therapy stages, provided that the interval between the end of neoadjuvant and/or adjuvant thera". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06636981
- Phase: 2
- Setting: All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial
- Sponsor: Fudan University
- Enrolled: 129

## Sources

- ClinicalTrials.gov NCT06636981: https://clinicaltrials.gov/study/NCT06636981

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Toripalimab](https://onco.cc/drugs/toripalimab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06636981.json